title: Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.
abstract: Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and updated in 2013 and 2016.
  
  
  
  To assess the effects of pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids for GBS.
  
  
  
  On 18 January 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for treatments for GBS. We also searched clinical trials registries.
  
  
  
  We included all randomised controlled trials (RCTs) or quasi-RCTs of acute GBS (within four weeks from onset) of all types and degrees of severity, and in individuals of all ages. We discarded trials that investigated only corticosteroids, intravenous immunoglobulin or plasma exchange. We included other pharmacological treatments or combinations of treatments compared with no treatment, placebo or another treatment. We also identified a number of non-randomised studies during the search, the results of which we considered in the Discussion.
  
  
  
  We followed standard Cochrane methodology.
  
  
  
  We identified no new trials during this update of the review. In previous versions of this review we identified only very low quality evidence for four different interventions published in four studies. Each study had a high risk of bias in at least one respect. One RCT with 19 participants comparing interferon beta-1a and placebo showed no clinically important difference in any outcome between groups. Another with 10 participants comparing brain-derived neurotrophic factor and placebo showed no clinically important difference in any outcome between groups. A third with 37 participants comparing cerebrospinal fluid filtration and plasma exchange also showed no clinically important difference in any outcome between groups. In a fourth with 43 participants, the risk ratio for an improvement by one or more disability grade after eight weeks was greater with the Chinese herbal medicine tripterygium polyglycoside than with corticosteroids (risk ratio 1.47; 95% confidence interval 1.02 to 2.11); other outcomes in this trial showed no difference. Serious adverse events were uncommon with each of these treatments and in the control groups.
  
  
  
  The quality of the evidence was very low. Three small RCTs, comparing interferon beta-1a or brain-derived neurotrophic factor with placebo, and cerebrospinal fluid filtration with plasma exchange, showed no significant benefit or harm for any of the interventions. A fourth small trial showed that the Chinese herbal medicine, tripterygium polyglycoside, hastened recovery in people with GBS to a greater extent than corticosteroids, but this result needs confirmation. We were unable to draw any useful conclusions from the few observational studies we identified.
authors.affiliation: Neuromuscular Unit 3 North, Charing Cross Hospital, Fulham Palace Road, London, UK, W6 8RF.
authors.forename: Jane
authors.initials: J
authors.lastname: Pritchard
authors.forename: Richard Ac
authors.initials: RA
authors.lastname: Hughes
authors.forename: Robert Dm
authors.initials: RD
authors.lastname: Hadden
authors.forename: Ruth
authors.initials: R
authors.lastname: Brassington
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D019208:Brain-Derived Neurotrophic Factor / Q000627:therapeutic use*; D002555:Cerebrospinal Fluid; D005374:Filtration; D020275:Guillain-Barre Syndrome / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D000068556:Interferon beta-1a / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use*; D028321:Plant Preparations / Q000627:therapeutic use*; D010951:Plasma Exchange; D016032:Randomized Controlled Trials as Topic; D029757:Tripterygium
chemical_list: D000305:Adrenal Cortex Hormones; D019208:Brain-Derived Neurotrophic Factor; D016756:Immunoglobulins, Intravenous; D028321:Plant Preparations; D016899:Interferon-beta; D000068556:Interferon beta-1a